AGS-004 achieved the trial’s primary endpoint of induction of T cell response to patient-specific HIV antigens. AGS-004 is a personalized HIV immunotherapy generated by the company’s Arcelis technology.
According to the company, Arcelis is an immunotherapy platform for creating personalized, RNA-loaded dendritic cell-based therapies perfectly matched to each patient’s unique virus.
John Bonfiglio, president and CEO of Argos, said: “We believe that these data support our multi-center Phase IIa trial investigating the efficacy of AGS-004 in improving the immune system’s ability to control viral replication in the absence of antiretroviral therapy.”
Argos also successfully demonstrated manufacturing feasibility and production consistency of AGS-004. AGS-004 is currently undergoing a Phase IIa proof-of-concept trial.